- Home
- SWZ vs STRO Comparison
SWZ vs STRO Comparison
Compare SWZ & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWZ
- STRO
- Stock Information
- Founded
- SWZ 1986
- STRO 2003
- Country
- SWZ United States
- STRO United States
- Employees
- SWZ N/A
- STRO N/A
- Industry
- SWZ Finance Companies
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SWZ Finance
- STRO Health Care
- Exchange
- SWZ Nasdaq
- STRO Nasdaq
- Market Cap
- SWZ 79.6M
- STRO 74.3M
- IPO Year
- SWZ N/A
- STRO 2018
- Fundamental
- Price
- SWZ $6.13
- STRO $0.90
- Analyst Decision
- SWZ
- STRO Hold
- Analyst Count
- SWZ 0
- STRO 7
- Target Price
- SWZ N/A
- STRO $1.97
- AVG Volume (30 Days)
- SWZ 14.2K
- STRO 520.3K
- Earning Date
- SWZ 01-01-0001
- STRO 11-12-2025
- Dividend Yield
- SWZ 6.59%
- STRO N/A
- EPS Growth
- SWZ N/A
- STRO N/A
- EPS
- SWZ N/A
- STRO N/A
- Revenue
- SWZ N/A
- STRO $104,473,000.00
- Revenue This Year
- SWZ N/A
- STRO $65.48
- Revenue Next Year
- SWZ N/A
- STRO N/A
- P/E Ratio
- SWZ N/A
- STRO N/A
- Revenue Growth
- SWZ N/A
- STRO N/A
- 52 Week Low
- SWZ $7.12
- STRO $0.52
- 52 Week High
- SWZ $8.57
- STRO $4.60
- Technical
- Relative Strength Index (RSI)
- SWZ 52.60
- STRO 49.98
- Support Level
- SWZ $6.11
- STRO $0.83
- Resistance Level
- SWZ $6.18
- STRO $1.01
- Average True Range (ATR)
- SWZ 0.05
- STRO 0.09
- MACD
- SWZ 0.01
- STRO -0.01
- Stochastic Oscillator
- SWZ 73.68
- STRO 19.40
About SWZ Swiss Helvetia Fund Inc. (The)
Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The group invests in various sectors such as pharmaceuticals, food and beverage, industrial goods and services, banks, personal and household goods, construction and materials, biotechnology, medical equipment, chemicals, technology, financial services, insurance, Semiconductors, Information Technology, and retail.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.